Spain Medical Device Registration & Market Access Guide (2026): AEMPS, Royal Decree 192/2023, CE Marking & Requirements
Everything you need to know about marketing medical devices in Spain in 2026 — including EU MDR requirements, AEMPS national registration database, Royal Decree 192/2023, EUDAMED deadlines, Spanish-language labeling mandates, clinical investigation procedures, post-market surveillance, autonomous region distributor notifications, and practical market entry guidance for one of Europe's largest healthcare markets.
Overview of Spain's Medical Device Market
Spain is one of the largest healthcare markets in Europe, with a medical devices market estimated at approximately $14.6 billion in 2025 and projected to grow to $27.45 billion by 2035, at a CAGR of approximately 6%. Spain's National Health System (SNS — Sistema Nacional de Salud) provides universal coverage to a population of approximately 48 million, with healthcare spending representing approximately 9.1% of GDP.
Spain's healthcare system is decentralized, with 17 autonomous communities (comunidades autónomas) managing healthcare delivery and procurement within their territories. This means market access strategies must account for both national registration requirements and regional procurement processes. The country has a strong and growing private healthcare sector, which provides additional commercial opportunities.
The Spanish medical device market is driven by an aging population (over 20% aged 65+), increasing prevalence of chronic diseases, and significant government investment in hospital infrastructure and digitalization. Spain is particularly strong in diagnostic imaging, cardiovascular devices, orthopedics, and digital health technologies. The connected medical devices segment alone was valued at approximately €2 billion in 2025, growing at a CAGR of 8%.
A landmark development for 2026: the EUDAMED mandatory registration deadline on 28 May 2026 will fundamentally change how devices are registered in Spain, complementing the national framework established by Royal Decree 192/2023 (effective since March 2023).
Key Market Data
| Metric | Value |
|---|---|
| Total market size (2025) | $14.6 billion (~€13.5 billion) |
| Projected market (2035) | $27.45 billion |
| CAGR (2025–2035) | 6% |
| Healthcare spending as % of GDP | ~9.1% |
| Population | ~48 million |
| Population aged 65+ | >20% |
| Autonomous communities | 17 |
| R&D spending in medical devices (est. 2025) | ~€1.5 billion |
Regulatory Framework
As an EU member state, Spain regulates medical devices primarily under EU-wide legislation, supplemented by national implementing laws and Spanish-specific registration requirements. Spain's regulatory framework for medical devices was significantly updated with the publication of Royal Decree 192/2023.
EU-Level Legislation
| Regulation | Purpose |
|---|---|
| Regulation (EU) 2017/745 (MDR) | Primary legislation for medical devices — classification, conformity assessment, CE marking, clinical evidence, post-market surveillance |
| Regulation (EU) 2017/746 (IVDR) | Primary legislation for in vitro diagnostic devices |
| Commission Implementing Decision (EU) 2025/2371 | Declares EUDAMED mandatory from 28 May 2026 |
National Legislation
| Law | Purpose |
|---|---|
| Royal Decree 192/2023 (Real Decreto 192/2023) | Effective March 21, 2023 — replaces RD 1591/2009 and RD 1616/2009. Consolidates national requirements for medical devices with EU MDR and IVDR. Covers custom-made devices, registration, clinical investigations, vigilance, and advertising |
| Royal Decree 1662/2000 | In vitro diagnostic medical devices (transitional provisions still apply for certain IVDR provisions) |
| Royal Legislative Decree 1/2015 | General health law framework |
| Ley 14/1986 (General Health Law) | Establishes the Spanish National Health System and its principles |
Key Regulatory Authorities
| Authority | Role |
|---|---|
| AEMPS (Agencia Española de Medicamentos y Productos Sanitarios) | Spanish Agency for Medicines and Medical Devices — primary competent authority for medical devices in Spain |
| Ministry of Health (Ministerio de Sanidad) | Oversees AEMPS and sets national health policy |
| Autonomous Community Health Authorities | 17 regional health authorities manage distributor notifications, regional procurement, and local healthcare delivery |
| Notified Bodies | AEMPS designates and supervises Notified Bodies operating in Spain |
AEMPS is responsible for:
- Registration of medical devices in the national database
- Designation and oversight of Notified Bodies
- Authorization of clinical investigations
- Post-market surveillance and vigilance coordination
- Enforcement of compliance within Spanish territory
- Managing the national medical device registry
- Licensing of manufacturing facilities for medical devices
CE Marking and Market Access
All medical devices placed on the Spanish market must bear the CE mark in accordance with the EU MDR. CE marking is the foundation, but Spain requires additional national registration and compliance with specific national provisions under Royal Decree 192/2023.
Steps to Market Access in Spain
Step 1: Classification (MDR Annex VIII)
- Classify your device under MDR rules (Class I, IIa, IIb, III)
- Classification is based on intended purpose, duration of contact, invasiveness, and active nature
Step 2: Conformity Assessment
- Class I (non-sterile, non-measuring, non-reusable surgical): Self-declaration by the manufacturer
- Class Is, Im, Ir, IIa, IIb, III: Involvement of a Notified Body is mandatory
- The Notified Body assesses your quality management system and technical documentation
Step 3: Technical Documentation
- Prepare a complete technical file in accordance with MDR Annexes II and III
- Include clinical evaluation, risk management, labeling, and instructions for use
Step 4: Declaration of Conformity and CE Marking
- Issue the EU Declaration of Conformity
- Affix the CE mark to the device and packaging
- Include the Notified Body number (for Class Is and above)
Step 5: AEMPS National Registration
- Register the device in the AEMPS online database before placing it on the Spanish market
- Submit required documentation including label, Spanish IFU, DoC, and CE certificate
- The product can be placed on the market as soon as the notification is processed in the database
Step 6: Appoint Authorized Representative (if non-Eu)
- Manufacturers outside the EU must appoint an EU Authorized Representative
- The AR must be registered in EUDAMED with a Single Registration Number (SRN)
AEMPS National Registration
Spain maintains a national medical device database administered by AEMPS. Under Royal Decree 192/2023, all medical devices placed on the Spanish market must be registered in this database before commercialization.
Note on the Marketing Register: Article 18 of Royal Decree 192/2023 created a new AEMPS Marketing Register that will eventually replace the current notification system. However, as of April 2026, this register is not yet fully operational because it is linked to the EUDAMED deployment timeline. The current notification system (online database) remains in use. Economic operators should monitor AEMPS communications for the transition timeline.
Registration Process
- Access the AEMPS online database portal
- Enter manufacturer and Authorized Representative information
- Input comprehensive device data:
- General device information and classification
- CE certification details
- UDI (Unique Device Identification) data
- Upload required documentation:
- Label (including Spanish description)
- Spanish IFU (Instructions for Use)
- Declaration of Conformity (DoC)
- CE certificate
- Submit notification — the product can be placed on the market as soon as the notification is processed
- AEMPS post-submission review: AEMPS will eventually review the submission to check accuracy and may follow up with additional questions
Critical: Annual Confirmation Requirement
Economic operators must update and/or confirm their company and device details in the AEMPS database annually. If details are not confirmed annually, AEMPS may delete the economic operator and device information from the database, requiring re-registration before continuing commercialization.
Registration Fees
Notifications for commercialization are subject to a fee of €99.71 per product, payable to AEMPS. Evaluation of devices for CE marking certification (when performed by AEMPS) ranges from €769.28 to €2,560.26, though most conformity assessments are performed by Notified Bodies rather than AEMPS directly.
Distributor Notification
Distributors and any entity established in Spain who intends to market medical devices, regardless of classification, must notify the start of their activity in advance to the health authority of the autonomous region where their registered office is located (Article 23, Royal Decree 192/2023). If they have warehouses in other regions, they must also notify the respective health authorities in those regions.
EUDAMED Registration
Under Commission Implementing Decision (EU) 2025/2371, the first four EUDAMED modules become mandatory on 28 May 2026. Spain is actively aligning its national registration systems with EUDAMED, with the AEMPS database expected to eventually interface with EUDAMED.
EUDAMED Modules and Deadlines
| Module | Content | Mandatory From |
|---|---|---|
| Actors | Registration of manufacturers, ARs, importers, sponsors | 28 May 2026 |
| UDI/Devices | Device registration with UDI data | 28 May 2026 |
| NB/Certificates | Notified Body certificate registration | 28 May 2026 |
| Market Surveillance | National authority market surveillance data | 28 May 2026 |
| Clinical Investigations | Under development | TBD |
| Vigilance | Under development | TBD |
Key Deadlines for Spain
| Deadline | Requirement |
|---|---|
| 28 May 2026 | All economic operators must be registered as Actors in EUDAMED. New MDR/IVDR devices must be registered in UDI/Devices before being placed on the Spanish market |
| 28 November 2026 | Legacy devices and devices already on the market before 28 May 2026 must be registered in EUDAMED |
| 28 May 2027 | Notified Bodies must register all MDR/IVDR certificates issued before the mandatory use date |
Spanish-Specific Requirements
While most requirements derive from the EU MDR, Spain imposes several additional national obligations under Royal Decree 192/2023.
1. Spanish-Language Labeling and Documentation
Spain requires that all labeling, instructions for use (IFU), and safety information be provided in Spanish. This is mandatory under Spanish law.
- Labels and packaging: Must be in Spanish (the label must include a Spanish description)
- Instructions for Use (IFU): Must be provided in Spanish
- Technical documentation: May be submitted in English
- AEMPS database entries: Key fields must be completed in Spanish
2. Manufacturing License
Manufacturing of medical devices in Spain requires a prior license granted by AEMPS. For custom-made medical devices, authorization is granted by the competent regional health authority. Requirements are set in Royal Decree 192/2023 and include:
- Evidence of adequate premises and technical equipment
- A qualified technical director
- Persons responsible for quality control and manufacturing activities
3. Clinical Investigations in Spain
Clinical investigations in Spain must comply with MDR Chapter VI, Annexes XIV and XV and national procedures overseen by AEMPS. Key requirements:
- Application to AEMPS with the documentation required by MDR
- Ethics Committee approval must be obtained
- Applications and supporting documentation must be submitted in Spanish
- Safety reporting follows MDR timelines, with reports submitted to AEMPS
- AEMPS has issued specific guidelines for conducting clinical investigations with medical devices in Spain
- Devices for clinical investigations must be provided free of charge by the sponsor, with all remaining products returned upon completion
4. Post-Market Surveillance and Vigilance
Spain operates within the EU vigilance framework while AEMPS monitors compliance at the national level. Key obligations include:
- Serious incidents: Must be reported to AEMPS within MDR timelines
- Field Safety Corrective Actions (FSCAs): Must be reported before or at the time of implementation
- Periodic Safety Update Reports (PSURs): Required under MDR Article 86
- Product recalls: Specifically regulated under Royal Decree 192/2023 and MDR Article 95
- AEMPS coordinates investigations and communicates risks through both national and EU channels
5. Custom-Made Devices
Royal Decree 192/2023 maintains specific provisions for custom-made medical devices. Manufacturers of custom-made devices must:
- Be authorized by the competent regional health authority (not AEMPS)
- Maintain documentation as specified by MDR
- Register the device in the AEMPS database (the Marketing Registry, though currently only operational for economic operators)
6. Extended Scope Under Royal Decree 192/2023
The new Royal Decree extends the scope of regulation to cover:
- Certain products that are similar to medical devices in terms of functioning and risks but do not have a medical purpose (e.g., aesthetic fillers, contact lenses for cosmetic purposes)
- Instruments for permanent or semi-permanent make-up or for skin tattooing using invasive techniques
Fees and Costs
Spain charges specific fees for AEMPS registration and certification activities. Overall market entry costs include EU-wide conformity assessment costs and Spanish-specific expenses:
| Item | Estimated Cost |
|---|---|
| AEMPS notification (per product) | €99.71 |
| AEMPS CE marking evaluation (if applicable) | €769.28–€2,560.26 |
| EUDAMED registration | No fee (EU system) |
| Notified Body assessment (Class IIa–III) | €15,000–€100,000+ depending on device class and complexity |
| Spanish-language translation (labeling/IFU) | €2,000–€25,000 depending on device complexity |
| EU Authorized Representative (for non-EU manufacturers) | €3,000–€15,000/year |
| Distributor notification (regional health authorities) | Typically no fee |
Total Estimated Cost to Market in Spain (CE Marking Included)
| Route | Estimated Total Cost |
|---|---|
| Class I (self-declaration) | €5,000–€20,000 (documentation, translations, AR, AEMPS notification) |
| Class IIa (via Notified Body) | €20,000–€65,000 (NB fees + documentation + translations + AR + AEMPS notification) |
| Class IIb/III (via Notified Body) | €50,000–€200,000+ (NB fees + clinical data + documentation + translations + AR + AEMPS notification) |
Timelines
| Step | Timeline |
|---|---|
| CE marking (Class I, self-declaration) | 1–3 months (documentation preparation) |
| CE marking (Class IIa, via NB) | 6–12 months |
| CE marking (Class IIb/III, via NB) | 12–24+ months |
| AEMPS database notification | 2–6 weeks (processed upon submission; AEMPS may review later) |
| EUDAMED Actor registration | 1–4 weeks |
| EUDAMED Device registration | 1–4 weeks per device |
| Manufacturing license (AEMPS) | Variable, typically 3–6 months |
| Clinical investigation authorization | Per MDR timelines, with additional Spanish-language preparation |
| Total market entry (CE + AEMPS) | Class I: 2–5 months; Class IIa: 7–14 months; Class IIb/III: 13–27+ months |
Practical Tips
Register in the AEMPS database early: The notification must be submitted before placing the product on the market. Prepare all documentation (especially Spanish translations) in advance to avoid delays.
Do not forget annual confirmation: Economic operators must update and confirm their AEMPS database entries annually. Failure to do so can result in deletion from the database, requiring complete re-registration. Set calendar reminders.
Notify the autonomous community: Distributors must notify the health authority of the autonomous region where they are established before starting activity. If you have warehouses in multiple regions, each requires a separate notification.
Prepare Spanish translations carefully: Spanish-language IFU and labeling are mandatory for AEMPS registration. Professional translation is essential — translation errors are a common cause of registration issues.
Budget for the AEMPS notification fee: While the €99.71 per product fee is modest, it adds up for large product portfolios. Factor this into your market entry budget.
Prepare for EUDAMED now: The 28 May 2026 deadline is firm. Complete Actor registration (SRN) and begin planning device data migration. Spain is aligning its national database with EUDAMED, and dual compliance will be required.
Understand regional procurement: Spain's decentralized healthcare system means procurement decisions are made at the autonomous community level. Develop relationships with regional health authorities and understand local tender processes.
Consider the custom-made device pathway: If applicable, the custom-made device pathway through regional health authorities (rather than AEMPS) can be faster, but has specific requirements and limitations.
Key Contacts and Resources
| Resource | URL/Contact |
|---|---|
| AEMPS (regulatory authority) | aemps.gob.es |
| Ministerio de Sanidad (Ministry of Health) | sanidad.gob.es |
| AEMPS Registration Database | aemps.gob.es (dispositivos médicos section) |
| EUDAMED (EU device database) | ec.europa.eu/tools/eudamed |
| Royal Decree 192/2023 | boe.es (Boletín Oficial del Estado) |
Summary Checklist for Market Entry in Spain
- Classify device under MDR (Class I, IIa, IIb, III)
- Complete conformity assessment (self-declaration or via Notified Body)
- Prepare technical documentation (MDR Annexes II & III)
- Issue Declaration of Conformity and affix CE mark
- Translate labeling and IFU into Spanish
- Appoint EU Authorized Representative (if non-EU)
- Register as Actor in EUDAMED (obtain SRN)
- Register device in EUDAMED UDI/Devices module
- Register device in AEMPS national database (pay €99.71 notification fee)
- Upload label, Spanish IFU, DoC, and CE certificate to AEMPS
- Set up annual confirmation reminder for AEMPS database
- Distributors: notify autonomous community health authority before starting activity
- (If manufacturing in Spain) Obtain AEMPS manufacturing license
- Implement post-market surveillance and vigilance procedures